CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that blood center
members representing 54% of the aggregate volume of platelets produced
by Blood Centers of America (BCA) have executed participation agreements
for adoption of the INTERCEPT Blood System.
In March, Cerus and BCA announced a 5-year agreement that called for BCA
to actively promote the INTERCEPT Blood System for platelets and plasma
to over 50 member blood centers, with a commitment to secure adoption
from member centers representing a minimum of 50% of BCA’s aggregate
volume.
“Our partnership with BCA has allowed its members to adopt INTERCEPT via
a simplified process,” commented William “Obi” Greenman, Cerus’
president and chief executive officer. “BCA members contracted for
INTERCEPT now represent 342,000 of the over 632,000 annual platelet
units distributed in total by the collective BCA organization. Several
of these centers are already actively using INTERCEPT, and we look
forward to working with the remainder as they look to deploy INTERCEPT.”
Individual BCA member centers that are now under contract for INTERCEPT
include:
|
|
|
|
|
Blood Bank of Delmarva
|
|
LIFELINE Blood Services
|
|
Blood Center of Wisconsin
|
|
LifeSouth Community Blood Centers
|
|
Blood Connection
|
|
Michigan Community Blood Centers
|
|
Central California Blood Center
|
|
Mississippi Valley Regional Blood Center
|
|
Central Pennsylvania Blood Bank
|
|
Oklahoma Blood Institute
|
|
Community Blood Center (Appleton)
|
|
Rhode Island Blood Center
|
|
Community Blood Center of the Carolinas
|
|
Shepeard Community Blood Center
|
|
Gulf Coast Regional Blood Center
|
|
Stanford Medical School Blood Center
|
|
Heartland Blood Centers
|
|
SunCoast Communities Blood Bank
|
|
Indiana Blood Center
|
|
UNYTS
|
|
|
|
|
“Cerus and BCA have worked together as a cohesive team over these past
few months,” said Bill Block, BCA’s president and chief executive
officer. “It has been a streamlined process for our members to adopt
INTERCEPT as their new safety standard.”
ABOUT BLOOD CENTERS OF AMERICA (BCA)
BCA is a member-owned organization comprised of independent blood
centers throughout North America that account for more than 30 percent
of the U.S. blood supply, distributing over 632,000 platelet and
1,000,000 plasma units to 2,000 hospitals annually. Along with their
core business of providing a substantial portion of the blood supply,
BCA members provide other services including patient blood management,
transfusion services, immunohematology testing, therapeutic apheresis,
and tissue and cord blood banking. In addition, BCA members provide a
variety of human blood products, cells and tissues to the therapeutic,
diagnostic, and cell therapy industries. You can find more information
regarding Blood Centers of America at http://bca.coop.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See www.cerus.com
for more information about Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160711005285/en/
Source: Cerus Corporation